Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 2.609
Filter
1.
Braz. dent. j ; 32(3): 21-31, May-June 2021. tab, graf
Article in English | LILACS, BBO | ID: biblio-1345507

ABSTRACT

Abstract This study assessed the fracture resistance of simulated immature teeth reinforced with calcium aluminate cement (CAC) or mineral trioxide aggregate (MTA) containing calcium carbonate nanoparticles (nano-CaCO3). The microstructural arrangement of the cements and their chemical constitution were also evaluated. Forty-eight canines simulating immature teeth were distributed into 6 groups (n=8): Negative control - no apical plug or root canal filling; CAC - apical plug with CAC; CAC/nano-CaCO3 - apical plug with CAC+5% nano-CaCO3; MTA - apical plug with MTA; MTA/nano-CaCO3 - apical plug with MTA+5% nano-CaCO3; and Positive control - root canal filling with MTA. The fracture resistance was evaluated in a universal testing machine. Samples of the cements were analyzed under Scanning Electron Microscope (SEM) to determine their microstructural arrangement. Chemical analysis of the cements was performed by Energy Dispersive X-ray Spectroscopy (EDS). The fracture resistance of CAC/nano-CaCO3 was significantly higher than the negative control (p<0.05). There was no significant difference among the other groups (p>0.05). Both cements had a more regular microstructure with the addition of nano-CaCO3. MTA samples had more calcium available in soluble forms than CAC. The addition of nano-CaCO3 to CAC increased the fracture resistance of teeth in comparison with the non-reinforced teeth. The microstructure of both cements containing nano-CaCO3 was similar, with a more homogeneous distribution of lamellar- and prismatic-shaped crystals. MTA had more calcium available in soluble forms than CAC.


Resumo Este estudo avaliou a resistência à fratura de dentes imaturos simulados reforçados com cimento de aluminato de cálcio (CAC) ou trióxido agregado mineral (MTA) contendo nanopartículas de carbonato de cálcio (nano-CaCO3). O arranjo microestrutural dos cimentos e sua constituição química também foram avaliados. Quarenta e oito caninos simulando dentes imaturos foram distribuídos em 6 grupos (n=8): Controle negativo - sem plug apical ou obturação do canal radicular; CAC - plug apical com CAC; CAC/nano-CaCO3 - plug apical com CAC + 5% nano-CaCO3; MTA - plug apical com MTA; MTA/nano-CaCO3 - plug apical com MTA + 5% nano-CaCO3; e Controle positivo - obturação dos canais radiculares com MTA. A resistência à fratura foi avaliada em máquina universal de ensaios. Amostras dos cimentos foram analisadas em Microscópio Eletrônico de Varredura (MEV) para determinar seu arranjo microestrutural. A análise química dos cimentos foi realizada por Espectroscopia de Energia Dispersiva de Raio-X (EDS). A resistência à fratura de CAC/nano-CaCO3 foi significativamente maior do que o controle negativo (p<0,05). Não houve diferença significativa entre os outros grupos (p>0,05). Ambos os cimentos apresentaram microestrutura mais regular com a adição de nano-CaCO3. As amostras de MTA apresentaram mais cálcio disponível em formas solúveis do que CAC. A adição de nano-CaCO3 ao CAC aumentou a resistência à fratura dos dentes em comparação aos dentes não reforçados. A microestrutura de ambos os cimentos contendo nano-CaCO3 foi semelhante, com uma distribuição mais homogênea de cristais de formato lamelar e prismático. MTA apresentou mais cálcio disponível nas formas solúveis do que CAC.


Subject(s)
Humans , Root Canal Filling Materials , Tooth Fractures , Oxides , Root Canal Obturation , Silicates , Calcium Compounds , Aluminum Compounds , Tooth Apex , Dental Cements , Drug Combinations
2.
Braz. dent. j ; 32(1): 53-58, Jan.-Feb. 2021. tab, graf
Article in English | LILACS, BBO | ID: biblio-1180728

ABSTRACT

Abstract The endodontic revascularization may be an alternative treatment for necrotic immature teeth, however, several treatment steps may cause tooth discoloration. This study evaluated the use of three calcium silicate-based cements with different radiopacifying agents on the color alteration (∆E) of extracted premolars after simulation of revascularization. Forty single rooted extracted premolars were shaped with #1-6 gates Glidden drills, rinsed with sodium hypochlorite, and filled with fresh human blood. Three calcium silicate-based cements with different radiopacifying agents (bismuth oxide - CSBi, calcium tungstate - CSW, and zirconium oxide - CSZr) were applied over the blood clot (n=10). The control group received the application of a temporary zinc oxide-based cement (TFZn) (n=10). ∆E was measured with a spectrophotometer, using the L*a*b* color system of the International Commission on Illumination (CIELab), in different times: prior to the preparation of the access cavity (t0); right after treatment (t1); and after one (t2), two (t3), three (t4) and four (t5) months. The tooth site for color evaluation was standardized by silicon matrix, the color reading was performed 3 times per tooth, and the teeth were stored in 37º water between evaluations. ∆E, whiteness (WID index) and yellowness (b*) were evaluated. Data were subjected to one-way ANOVA and repeated measures ANOVA, followed by Tukey's post hoc test (α=0.05). All groups were similar in ∆E1 (t0-t1). The ∆E was the lowest and constant in the control group. In all evaluation times, CSBi presented the highest ∆E (p<0.01). CSW and CSZr were similar in all evaluated times and presented intermediate ∆E values. WID index from CSBi and CSW presented more distancing from 'white' reference. CSBi presented the greatest decrease in yellowness (b* value). The cement containing bismuth oxide presented the highest color alteration values. All tested calcium silicate-based cements presented clinically perceptible discoloration. Calcium tungstate and zirconium oxide may be used as alternative radiopacifiers to decrease tooth discoloration after endodontic tooth revascularization.


Resumo A revascularização endodôntica pode ser um tratamento alternativo para dentes imaturos necrosados, porém, várias etapas do tratamento podem causar alteração de cor dental. Este estudo avaliou o uso de três cimentos a base de silicato de cálcio com diferentes agentes radiopacificadores na alteração de cor (∆E) de pré-molares extraídos após a simulação de revascularização. Quarenta pré-molares unirradiculares extraídos foram conformados com brocas gates glidden #1-6, irrigados com hipoclorito de sódio, e preenchidos com sangue humano fresco. Três cimentos a base de silicato de cálcio com diferentes agentes radiopacificadores (óxido de bismuto - CSBi, tungstato de cálcio - CSW, e óxido de zircônio - CSZr) foram aplicados sobre o coágulo sanguíneo (n=10). O grupo controle recebeu a aplicação de um cimento temporário a base de óxido de zinco (TFZn) (n=10). ∆E foi medida com um espectrofotômetro, utilizando o sistema de cor L*a*b* da International Commission on Illumination (CIELab), em tempos diferentes: previamente ao preparo da cavidade de acesso (t0); logo após o tratamento (t1); e após um (t2), dois (t3), três (t4) e quatro (t5) meses. O local do dente para a avaliação de cor foi padronizado por uma matriz de silicone, a leitura da cor foi realizada 3 vezes por dente, e os dentes foram armazenados em água a 37ºC entre as avaliações. ∆E, 'clareamento' (índice WID) e tom amarelado (b*) foram avaliados. Os dados foram submetidos ao teste de ANOVA um fator e teste ANOVA de medidas repetidas, seguidos pelo teste post hoc de Tukey (α=0,05). Todos os grupos foram semelhantes em ∆E1 (t0-t1). A ∆E foi menor e constante no grupo controle. Em todos os tempos de avaliação, CSBi apresentou os maiores valores de ∆E (p<0.01). CSW e CSZr foram semelhantes em todos os tempos avaliados e apresentaram valores intermediários de ∆E. O índice WID de CSBi e CSW se distanciaram mais da referência 'branco'. CSBi apresentou maior diminuição no tom amarelado (valor de b*) os outros grupos. O cimento contendo óxido de bismuto apresentou os maiores valores de alteração de cor. Todos os cimentos testados apresentaram alteração de cor clinicamente perceptível. O tungstato de cálcio e óxido de zircônio podem ser usados como radiopacificares alternativos para a diminuição da alteração de cor dental após o processo de revascularização endodontica.


Subject(s)
Humans , Root Canal Filling Materials , Tooth Discoloration , Oxides , Silicates , Calcium Compounds , Aluminum Compounds , Dental Cements , Drug Combinations
3.
Braz. dent. j ; 32(1): 42-47, Jan.-Feb. 2021. tab, graf
Article in English | LILACS, BBO | ID: biblio-1180727

ABSTRACT

Abstract New methodologies using micro-CT to evaluate solubility besides dimensional and morphological changes of endodontic materials are proposed. However, there is no standardization in the methods. The aim of this study was to assess the effect of different dimensions of test samples on volumetric change evaluation of different endodontic materials. AH Plus, FillCanal and Sealapex root canal sealers, Biodentine, IRM and MTA root-end filling cements were used in the tests. Samples of each material with a thickness of 1.5 mm and different diameters were manufactured: 6.3, 7.75, and 9.0 mm. The samples were scanned in micro-computed tomography (micro-CT) after setting and after 7 days of immersion in distilled water. The volumetric change was evaluated by means of the difference in the total volume of the specimens before and after immersion. Data were submitted to ANOVA and Tukey tests (p<0.05). The size of the samples did not affect the percentage of volumetric change of the materials (p>0.05). All sample sizes had greater volume loss for Sealapex among the sealers and Biodentine for the cements (p<0.05). In conclusion, Biodentine and Sealapex had the highest volume loss after immersion. Samples with 1.5 mm thickness, and diameters ranging between 6.3 and 9.0 mm can be used to assess the stability of endodontic materials using micro-CT without affecting the percentage of volumetric change.


Resumo Novas metodologias utilizando micro-CT são propostas para avaliar a solubilidade além de alterações dimensionais e morfológicas em materiais endodônticos. No entanto, não há padronização nos métodos. O objetivo deste estudo foi avaliar o efeito de diferentes dimensões de corpos de prova na avaliação da alteração volumétrica de diferentes materiais endodônticos. Os cimentos obturadores AH Plus, FillCanal e Sealapex e os cimentos retrobturadores Biodentine, IRM e MTA foram utilizados nos testes. Foram confeccionadas amostras de cada material com espessura de 1.5 mm e diâmetros diferentes: 6.3, 7.75 e 9.0 mm. As amostras foram escaneadas em microtomografia computadorizada (micro-CT) após a presa e após 7 dias de imersão em água destilada. A alteração volumétrica foi avaliada por meio da diferença no volume total dos corpos de prova antes e após a imersão. Os dados foram submetidos aos testes ANOVA e Tukey (p<0,05). A dimensão das amostras não afetou o percentual de alteração volumétrica dos materiais (p>0,05). Todos os diâmetros de amostra mostraram maior perda de volume para Sealapex entre os cimentos obturadores e Biodentine entre os cimentos retrobturadores (p<0,05). Como conclusão, Biodentine e Sealapex mostraram a maior perda volumétrica após a imersão. Amostras com 1.5 mm de espessura e diâmetros variando entre 6.3 e 9.0 mm podem ser usadas para avaliação da estabilidade de materiais endodônticos utilizando micro-CT, sem influenciar no percentual de alteração volumétrica.


Subject(s)
Root Canal Filling Materials , Oxides , Root Canal Obturation , Materials Testing , Calcium Compounds , Drug Combinations , Epoxy Resins , X-Ray Microtomography
4.
Article in Chinese | WPRIM | ID: wpr-879198

ABSTRACT

Drug combination is a common clinical phenomenon. However, the scientific implementation of drug combination is li-mited by the weak rational evaluation that reflects its clinical characteristics. In order to break through the limitations of existing evaluation tools, examining drug-to-drug and drug-to-target action characteristics is proposed from the physical, chemical and biological perspectives, combining clinical multicenter case resources, domestic and international drug interaction public facilities with the aim of discovering the common rules of drug combination. Machine learning technology is employed to build a system for evaluating and predicting the rationality of clinical drug combinations based on "drug characteristics-repository information-artificial intelligence" strategy, which will be debugged and validated in multi-center clinical practice, with a view to providing new ideas and technical references for the safety and efficacy of clinical drug use.


Subject(s)
Artificial Intelligence , Drug Combinations , Machine Learning , Technology
5.
Mem. Inst. Oswaldo Cruz ; 116: e200603, 2021. tab, graf
Article in English | LILACS | ID: biblio-1340225

ABSTRACT

BACKGROUND In March 2020, the World Health Organization (WHO) launched the Solidarity Program, probably the largest global initiative to encourage and support research in four promising drugs, named Remdesivir, Hydroxychloroquine, β Interferon and the combination Lopinavir / Ritonavir, to reduce the mortality of Coronavirus disease 2019 (COVID-19). OBJECTIVES Considering the potential impact of Solidarity Program to restrain the current pandemic, the present study aims to investigate whether it was designed upon indicators of scientific productivity, defined as the level of the production of new scientific knowledge and of the institutional capabilities, estimated in terms of scientific publications and technological agreements. METHODS The scientific documents on Alphacoronavirus, Betacoronavirus, Gammacoronavirus and Coronavirus were retrieved from Scopus database while the technological agreements on coronavirus were obtained through Cortellis. As for the institutions and countries, we have considered the data on author's affiliations in both set of data. For comparison, we included the analysis of documents related with other drugs or therapies, such as vaccines and antibodies, which were listed in a Clarivate's report on coronaviruses research. FINDINGS Most of the analysis refers to documents on Coronavirus, the largest group. The number of documents related to WHO's drugs are almost five times higher than in the other groups. This subset of documents involves the largest and most diverse number of institutions and countries. As for agreements, we observed a smaller number of institutions involved in it, suggesting differences between countries in terms of technical and human capabilities to develop basic and/or clinical research on coronavirus and to develop new forms or products to treat or to prevent the disease. MAIN CONCLUSIONS Hence, the results shown in this study illustrate that decisions taken by an international scientific body, as WHO, were mainly based in scientific knowledge and institutional competencies.


Subject(s)
Humans , Antiviral Agents/therapeutic use , COVID-19 , World Health Organization , Drug Combinations , SARS-CoV-2
6.
Adv Rheumatol ; 61: 7, 2021. tab, graf
Article in English | LILACS | ID: biblio-1152749

ABSTRACT

Abstract Objectives: To compare the efficacy and safety of a new formulation of a fixed dose combination of glucosamine sulfate (GS; 1500 mg) and bovine chondroitin sulfate (CS; 1200 mg) versus the reference product (RP) in patients with knee osteoarthritis (OA). Methods: In this multicenter, randomized, single-blind trial, 627 patients with knee osteoarthritis (OA)—Kellgren-Lawrence grades 2 or 3 and mean score ≥ 40 mm in the WOMAC pain subscale—were randomized to receive GS/ CS or the RP for 24 weeks. The primary efficacy endpoint was the absolute change in WOMAC pain subscale score. The secondary endpoints included the following: WOMAC total and subscale scores, overall assessment of the disease by the patient and the investigator, SF-12 score, OMERACT-OARSI response rate to the treatment, and rescue medication use. Results: Mean reductions of WOMAC pain score were - 35.1 (sd = 23.2) mm in the GS/CS group and - 36.5 (sd = 24.9) mm in the RP group. The difference between the adjusted means of both treatments confirmed the noninferiority of GS/CS versus the RP. Improvement was observed in pain, stiffness, physical function and total WOMAC score, as well as in overall OA assessment by the patient and the investigator for both groups. No improvement was observed in SF-12. The rate of OMERACT-OARSI responders was 89.4% in GS/CS group and 87.9% in the RP group. Headache and changes in glucose tolerance were the most frequent treatment-related adverse events. Conclusions: The new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin sulfate was non-inferior to the RP in symptomatic treatment of knee OA, with a high responder rate and good tolerability profile. Trial registration: ClinicalTrials.gov; Registration number NCT02830919; Date of registration: July 13, 2016; First randomization date: December 05, 2016).(AU)


Subject(s)
Humans , Chondroitin/therapeutic use , Osteoarthritis, Knee/drug therapy , Drug Combinations , Glucosamine/therapeutic use , Single-Blind Method , Treatment Outcome
7.
Rev. Soc. Bras. Med. Trop ; 54: e05362020, 2021. tab, graf
Article in English | LILACS | ID: biblio-1155593

ABSTRACT

Abstract INTRODUCTION: Artemisinin-based combination therapy (ACT), such as artemisinin-piperaquine (AP), dihydroartemisinin-piperaquine (DP), and artemether-lumefantrine (AL), is the first-line treatment for malaria in many malaria-endemic areas. However, we lack a detailed evaluation of the cardiotoxicity of these ACTs. This study aimed to analyze the electrocardiographic effects of these three ACTs in malaria patients. METHODS: We analyzed the clinical data of 89 hospitalized patients with falciparum malaria who had received oral doses of three different ACTs. According to the ACTs administered, these patients were divided into three treatment groups: 27 treated with AP (Artequick), 31 with DP (Artekin), and 31 with AL (Coartem). Electrocardiograms and other indicators were recorded before and after the treatment. The QT interval was calculated using Fridericia's formula (QTcF) and Bazett's formula (QTcB). RESULTS: Both QTcF and QTcB interval prolongation occurred in all three groups. The incidence of such prolongation between the three groups was not significantly different. The incidence of both moderate and severe prolongation was not significantly different between the three groups. The ΔQTcF and ΔQTcB of the three groups were not significantly different. The intra-group comparison showed significant prolongation of QTcF after AL treatment. CONCLUSIONS: Clinically recommended doses of DP, AL, and AP may cause QT prolongation in some malaria patients but do not cause torsades de pointes ventricular tachycardia or other arrhythmias.


Subject(s)
Humans , Malaria, Falciparum/drug therapy , Artemisinins/adverse effects , Malaria/drug therapy , Antimalarials/adverse effects , Quinolines , Drug Combinations , Electrocardiography , Artemether/therapeutic use , Artemether, Lumefantrine Drug Combination/therapeutic use
8.
Braz. oral res. (Online) ; 35: e086, 2021. tab, graf
Article in English | LILACS, BBO | ID: biblio-1285724

ABSTRACT

Abstract This study evaluated the cytotoxicity, the antimicrobial and physicochemical properties of root canal sealers incorporated with phytotherapic Uncaria tomentosa (UT). Unmodified AH Plus (Dentsply, DeTrey, Germany) and MTA Fillapex (Angelus, Londrina, Brazil) were used as controls. UT was incorporated into AH Plus and MTA Fillapex, at concentrations of 2% and 5% of the total weight of these sealers (w/w). Flowability, setting time, and solubility were evaluated following ISO requirements. The pH values were measured at periods of 12, 24, 48 hours, and 7 days. The antimicrobial activity of the sealers against Enterococcus faecalis was analyzed by both direct contact tests in freshly prepared sealers, and after 7 days. The cytotoxicity of the samples was evaluated by the MTT assay, to check Balb/c 3T3 cell viability. The statistical analysis was performed by one-way ANOVA and Tukey's test (p < 0.05). The incorporation of UT was associated with a decrease in flow, for both sealers, an increase in AH Plus setting time, increase in MTA Fillapex pH values, and solubility (after 14 days), for both sealers (p < 0.05). Regarding the antibacterial evaluation, bacterial reduction was reported after incorporation of UT into both AH Plus and MTA Fillapex, up to 7 days after handling of the material (P<0.05). UT incorporation decreased the cytotoxic effects of both AH Plus and MTA Fillapex sealers in a way directly proportional to their respective concentrations (p < 0.05). In conclusion, UT can be added to both sealers to reduce their cytotoxicity, and improve their antibacterial effects, without compromising their original physicochemical properties.


Subject(s)
Humans , Root Canal Filling Materials/toxicity , Cat's Claw , Oxides , Materials Testing , Silicates , Calcium Compounds , Drug Combinations , Epoxy Resins/toxicity , Anti-Bacterial Agents/toxicity
9.
Braz. oral res. (Online) ; 35: e077, 2021. tab, graf
Article in English | LILACS, BBO | ID: biblio-1278594

ABSTRACT

Abstract This study evaluated the physicochemical, biological, and antimicrobial properties of a new hydraulic calcium silicate-based modified material, and compared it with MTA Repair HP and MTA Angelus. The materials were assessed regarding color luminosity (L), color change, radiopacity, setting time, and ISO 6876:2012 linear flow. Volumetric filling and volume change were evaluated using microcomputed-tomography (µCT). Chemical characterization after 28 days in Hank's Balanced Salt Solution (HBSS) and pH analysis were also assessed. Biological characterization of cytotoxicity and microbiological assessment were also undertaken. Shapiro-Wilk, ANOVA, Levene and post hoc analyses with Bonferroni correction were performed, adopting a 5% significance level (p <0.05). Bio-C Pulpo exhibited the highest L values after 90 days. All tested materials demonstrated color change during the analyses, and had radiopacity above 5 mm Al. MTA Repair HP set faster than Bio-C Pulpo, whereas the latter had the highest linear flow. MTA Repair HP had the highest volumetric filling in µCT analysis. Bio-C Pulpo showed the highest alkalinity during all tested periods, and the highest volumetric loss (above 9%), in comparison with MTA Repair HP and MTA Angelus. Bio-C Pulpo did not form calcium hydroxide after hydration. MTA Repair HP demonstrated the highest cytocompatibility, and Bio-C Pulpo, the highest cytotoxicity. No inhibition halos were observed for any material, and similar higher turbidity values were seen after direct contact. Composition additives used in Bio-C Pulpo modified its properties, and both the absence of calcium hydroxide deposition after hydration, and the related cytotoxicity of this material are of particular concern.


Subject(s)
Root Canal Filling Materials/toxicity , Aluminum Compounds/toxicity , Oxides/toxicity , Materials Testing , Calcium , Silicates/toxicity , Calcium Compounds/toxicity , Drug Combinations
10.
Rev. medica electron ; 42(6): 2540-2559, nov.-dic. 2020. tab, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1150036

ABSTRACT

RESUMEN Introducción: se sabe que las concentraciones plasmáticas de hormona antidiurética o vasopresina son más altas en las mujeres con dismenorrea primaria (DiPr) y podría ser causa de retención de agua con signos y síntomas concomitantes que agravan su cuadro clínico. La monoterapia con AINEs en ocasiones alcanza solo un alivio parcial porque no incide sobre la vasopresina. Objetivo: evaluar la eficacia y tolerabilidad del dexketoprofeno + pamabrom en la DiPr tomando como referencia el acetaminofén. Materiales y métodos: estudio doble ciego, controlado, randomizado, en pacientes con DiPr asignados al azar. Fueron aleatorizadas 172 pacientes, 86 en cada grupo 1) Grupo casos (DP): dexketoprofeno + pamabrom o 2) Grupo control (AC): acetaminofén. Se evaluó la evolución de la intensidad del dolor, el alivio del dolor, la gravedad de otros síntomas presentes y la satisfacción global del médico y paciente. Se registró las reacciones adversas. Resultados: la disminución de la intensidad del dolor, de los síntomas acompañantes y el alivio del dolor evaluados por la EVA, la PID, la SPID, el PAR y el TOTPAR respectivamente es mayor y más rápida de modo significativo en todos los tiempos para la combinación DP. Las reacciones adversas fueron mínimas. La satisfacción global de pacientes y médicos respecto al tratamiento es significativa a favor de la combinación DP. Conclusiones: dexketoprofeno + pamabrom es significativamente más eficaz y rápido en el control del dolor y otros síntomas presentes en la dismenorrea primaria que acetaminofén demostrando la validez de añadir un diurético suave a un AINE para incrementar su eficacia. El tratamiento DP es bien tolerado (AU).


ABSTRACT Background: It is known that plasma concentrations of antidiuretic hormone or vasopressin are higher in women with primary dysmenorrhea (DiPr) and could cause water retention with concomitant signs and symptoms that aggravate the illness. Monotherapy with NSAIDs sometimes achieves only partial relief because it does not affect vasopressin. Objective: The aim was to evaluate the efficacy and tolerability of dexketoprofen + pamabrom in DiPr taking as reference acetaminophen. Materials and methods: Double-blind, controlled, randomized study in patients with DiPr random to 1) Case group (PD): dexketoprofen + pamabrom or 2) Control group (CA): acetaminophen. The evolution of pain intensity, pain relief, severity of other present symptoms and overall satisfaction of the doctor and patient were evaluated. Adverse reactions were recorded. Results: 172 patients were randomized, 86 in each group. The decrease in pain intensity, accompanying symptoms and pain relief evaluated by VAS, PID, SPID, PAR and TOTPAR respectively is significantly greater and faster at all times for the combination DP. Adverse reactions were minimal. The overall satisfaction of patients and doctors regarding treatment is significant in favor of the DP combination. Conclusions: Dexketoprofen + pamabrom is significantly more effective and faster in the control of pain and other symptoms present in primary dysmenorrhea than acetaminophen demonstrating the validity of adding a mild diuretic to an NSAID to increase its effectiveness. DP treatment is well tolerated (AU).


Subject(s)
Humans , Female , Vasopressins/pharmacology , Dysmenorrhea/drug therapy , Treatment Outcome , Drug Combinations , Dysmenorrhea/classification , Dysmenorrhea/metabolism , Dysmenorrhea/pathology , Observational Studies as Topic
11.
Arq. bras. cardiol ; 115(5): 821-827, nov. 2020. tab
Article in Portuguese | LILACS, SES-SP | ID: biblio-1142272

ABSTRACT

Resumo Fundamento O tratamento com sacubitril-valsartana teve seu benefício prognóstico confirmado no ensaio PARADIGM-HF. No entanto, dados sobre alterações no teste de esforço cardiopulmonar (TECP) com o uso de sacubitril-valsartana são escassos. Objetivo O objetivo deste estudo foi comparar os parâmetros do TECP antes e depois do tratamento com sacubitril-valsartana. Métodos Avaliação prospectiva de pacientes com insuficiência cardíaca (IC) crônica e fração de ejeção do ventrículo esquerdo ≤40%, mesmo sob terapia padrão otimizada, que iniciaram tratamento com sacubitril-valsartana, sem expectativa de tratamentos adicionais para a IC. Os dados do TECP foram coletados na semana anterior e 6 meses depois do tratamento com sacubitril-valsartana. Diferenças estatísticas com valor p <0,05 foram consideradas significativas. Resultados De 42 pacientes, 35 (83,3%) completaram o seguimento de 6 meses, uma vez que 2 (4,8%) morreram e 5 (11,9%) interromperam o tratamento devido a eventos adversos. A média de idade foi de 58,6±11,1 anos. A classe NYHA (classificação da New York Heart Association) melhorou em 26 (74,3%) pacientes. O consumo máximo de oxigênio (VO2max) (14,4 vs. 18,3 ml/kg/min, p<0,001), a inclinação VE/VCO2 (36,7 vs. 31,1, p<0,001) e a duração do exercício (487,8 vs. 640,3 s, p<0,001) também melhoraram com o uso de sacubitril-valsartana. O benefício foi mantido mesmo com a dose de 24/26 mg (13,5 vs. 19,2 ml/kg/min, p=0,018) de sacubitril-valsartana, desde que esta tenha sido a maior dose tolerada. Conclusões O tratamento com sacubitril-valsartana está associado a uma melhora acentuada do VO2max, da inclinação VE/VCO2 e da duração do exercício no TECP. (Arq Bras Cardiol. 2020; [online].ahead print, PP.0-0)


Abstract Background Sacubitril/valsartan had its prognosis benefit confirmed in the PARADIGM-HF trial. However, data on cardiopulmonary exercise testing (CPET) changes with sacubitril-valsartan therapy are scarce. Objective This study aimed to compare CPET parameters before and after sacubitril-valsartan therapy. Methods Prospective evaluation of chronic heart failure (HF) patients with left ventricular ejection fraction ≤40% despite optimized standard of care therapy, who started sacubitril-valsartan therapy, expecting no additional HF treatment. CPET data were gathered in the week before and 6 months after sacubitril-valsartan therapy. Statistical differences with a p-value <0.05 were considered significant. Results Out of 42 patients, 35 (83.3%) completed the 6-month follow-up, since 2 (4.8%) patients died and 5 (11.9%) discontinued treatment for adverse events. Mean age was 58.6±11.1 years. New York Heart Association class improved in 26 (74.3%) patients. Maximal oxygen uptake (VO2max) (14.4 vs. 18.3 ml/kg/min, p<0.001), VE/VCO2slope (36.7 vs. 31.1, p<0.001), and exercise duration (487.8 vs. 640.3 sec, p<0.001) also improved with sacubitril-valsartan. Benefit was maintained even with the 24/26 mg dose (13.5 vs. 19.2 ml/kg/min, p=0.018) of sacubitril-valsartan, as long as this was the highest tolerated dose. Conclusions Sacubitril-valsartan therapy is associated with marked CPET improvement in VO2max, VE/VCO2slope, and exercise duration. (Arq Bras Cardiol. 2020; [online].ahead print, PP.0-0)


Subject(s)
Humans , Middle Aged , Aged , Ventricular Function, Left , Heart Failure/drug therapy , Oxygen , Stroke Volume , Tetrazoles , Prospective Studies , Treatment Outcome , Drug Combinations , Angiotensin Receptor Antagonists , Aminobutyrates
13.
Braz. dent. j ; 31(6): 680-684, Nov.-Dec. 2020. graf
Article in English | LILACS, BBO | ID: biblio-1132355

ABSTRACT

Abstract This case report discusses the endodontic treatment of a 7-year-old girl who suffered trauma (intrusion) to the immature upper central incisors secondary to a fall from a bicycle. Thirty days after the accident the patient was brought by her mother for clinical and radiographic assessment with a chief complaint of swelling and tenderness to percussion and palpation. Acute apical abscess associated with immature teeth were diagnosed. A decision was made to perform regenerative endodontic treatment. Access cavities were made and the root canals were disinfected by irrigation with 2.5% sodium hypochlorite. Final irrigation was performed with 17% EDTA. Due to pain and presence of secretions, 2% chlorhexidine gel was applied as an intracanal medicament. Seven days later, at the second visit, the root canals were once again disinfected and the canals of the right and left permanent upper central incisors were filled with double antibiotic paste (metronidazole/ciprofloxacin) and calcium hydroxide paste, respectively. Zinc oxide was mixed in both pastes. At the third visit, after 21 more days, the pastes were removed and the periapical areas were stimulated with a #80 K-file to encourage clot formation within the pulp cavities. A mineral trioxide aggregate (MTA) paste cervical plug was placed and the teeth were restored with glass ionomer cement. Radiographs and CBCT scans demonstrated complete root formations. The patient has been followed for 12 years, with evidence of clinical success throughout.


Resumo Este relato de caso discute o tratamento endodôntico de uma menina de 7 anos que sofreu trauma nos incisivos centrais superiores imaturos, após queda de bicicleta. Trinta dias após o acidente, a paciente foi levada pela mãe para avaliação clínica e radiográfica com queixa principal de inchaço e sensibilidade à percussão e palpação. Foram diagnosticados abscessos apicais agudos em ambos os dentes. Foi decidido por realizar o tratamento endodôntico regenerativo. Após acessos coronários, os canais radiculares foram submetidos à protocolos de antissepsia com auxílio de irrigação com hipoclorito de sódio a 2,5% e EDTA 17%. Devido à dor e presença de secreções, foi utilizada medicação intracanal com clorexidina gel 2% por 7 dias. Na segunda sessão, os canais radiculares foram novamente submetidos aos procedimentos de antissepsia e os canais dos incisivos centrais superiores permanentes direito e esquerdo foram preenchidos com pasta antibiótica dupla (Metronidazol / Ciprofloxacina) e pasta de hidróxido de cálcio, respectivamente. Em ambas as pastas foi adicionado o óxido de zinco. Na terceira sessão, após mais 21 dias, as pastas foram removidas e as regiões periapicais foram estimuladas com lima K nº 80 para incentivar a formação de coágulos sanguíneos no interior das cavidades pulpares. Tampões cervicais de MTA foram adaptados e os dentes restaurados com cimento de ionômero de vidro resinoso. Radiografias e tomografias computadorizadas demonstraram formações radiculares completas. A paciente é acompanhada há 12 anos, com evidências clínicas e radiográficas de sucesso.


Subject(s)
Humans , Female , Child , Regenerative Endodontics , Incisor , Oxides , Follow-Up Studies , Silicates , Calcium Compounds , Dental Pulp Necrosis , Abscess , Drug Combinations
14.
Braz. dent. j ; 31(5): 511-515, Sept.-Oct. 2020. tab
Article in English | LILACS, BBO | ID: biblio-1132334

ABSTRACT

Abstract This study aimed to assess the physicochemical properties of a repair material in the Brazilian market, BioMTA, in comparison to other two materials currently in use (Biodentine and MTA Angelus). The initial setting time was evaluated using Gillmore needle. The pH was measured with a pH-meter after 24 h, 3, 7, 14 and 21 days. The radiopacity was determined using the equivalence in millimeters of aluminum (mm Al) from digitized occlusal radiographs. Solubility was determined after immersion in water for 7 days. The data were analyzed by one-way ANOVA and Tukey tests (a=0.05). The BioMTA initial setting time (5.2 min) was lower than the other materials (p<0.05). All materials showed an alkaline pH at 21 days. At 24 h, BioMTA was the most alkaline material (p<0.05); and at 3, 7, 14 and 21 days there was no difference between BioMTA and Biodentine (p>0.05), both being more alkaline than MTA Angelus (p<0.05). The radiopacity of BioMTA (4.2 mm Al) was significantly higher compared to Biodentine (p<0.05) and lower than MTA Angelus (p<0.05). The solubility of the materials was -4.2%, -1.6% and 4.1% for BioMTA, MTA Angelus and Biodentine, respectively, with a significant difference between them (p<0.05). Therefore, it can be concluded that BioMTA displayed a shorter setting time, an alkaline pH, a higher radiopacity, and a gain in mass.


Resumo Este estudo teve como objetivo avaliar as propriedades físico-químicas de um material reparador disponível no mercado brasileiro, BioMTA, em comparação com outros dois materiais atualmente em uso (Biodentine e MTA Angelus). O tempo de presa inicial foi avaliado usando a agulha de Gillmore. O pH foi medido com um pH-metro após 24 h, 3, 7, 14 e 21 dias. A radiopacidade foi determinada aplicando a equivalência em milímetros de alumínio (mm Al) de radiografias oclusais digitalizadas. A solubilidade foi determinada após imersão em água por 7 dias. Os dados foram analisados ​​por meio dos testes ANOVA de uma via e Tukey (a=0,05). O tempo de presa inicial do BioMTA (5,2 min) foi menor do que os outros materiais (p<0,05). Todos os materiais apresentaram pH alcalino aos 21 dias. Às 24 h, o BioMTA foi o material mais alcalino (p<0,05); e aos 3, 7, 14 e 21 dias não houve diferença entre BioMTA e Biodentine (p>0,05), sendo ambos mais alcalinos que MTA Angelus (p<0,05). A radiopacidade do BioMTA (4,2 mm Al) foi significativamente maior em comparação ao Biodentine (p<0,05) e menor que o MTA Angelus (p<0,05). A solubilidade dos materiais foi de -4,2%, -1,6% e 4,1% para BioMTA, MTA Angelus e Biodentine, respectivamente, havendo diferença significativa entre eles (p<0,05). Portanto, pode-se concluir que o BioMTA apresentou um menor tempo de presa, pH alcalino, uma alta radiopacidade e um ganho em massa.


Subject(s)
Root Canal Filling Materials , Silicates , Oxides , Solubility , Acrylic Resins , Materials Testing , Brazil , Water , Calcium Compounds , Aluminum Compounds , Drug Combinations
15.
Brasília; s.n; 8 ago. 2020.
Non-conventional in Portuguese | LILACS, BRISA, PIE | ID: biblio-1117974

ABSTRACT

O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referentes ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 16 artigos e 4 protocolos.


Subject(s)
Humans , Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Betacoronavirus/drug effects , Ozone/therapeutic use , Technology Assessment, Biomedical , Immunoglobulins/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , BCG Vaccine/therapeutic use , Cross-Sectional Studies , Cohort Studies , Adrenal Cortex Hormones/therapeutic use , Ritonavir/therapeutic use , Drug Combinations , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Mesenchymal Stem Cells , Lopinavir/therapeutic use , Darunavir/therapeutic use , Hydroxychloroquine/therapeutic use
16.
Brasília; s.n; 7 ago. 2020.
Non-conventional in Portuguese | LILACS, BRISA, PIE | ID: biblio-1117973

ABSTRACT

O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referentes ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 12 artigos e 4 protocolos.


Subject(s)
Humans , Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Betacoronavirus/drug effects , Renin-Angiotensin System , Technology Assessment, Biomedical , Dexamethasone/therapeutic use , Vaccines/therapeutic use , Chloroquine/therapeutic use , Interferons/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Azithromycin/therapeutic use , Heparin, Low-Molecular-Weight/therapeutic use , Ritonavir/therapeutic use , Drug Combinations , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Lopinavir/therapeutic use , Rituximab/therapeutic use , Hydroxychloroquine/therapeutic use
17.
Goiânia; SES-GO; 10 jul. 2020. 1-7 p.
Non-conventional in Portuguese | LILACS, ColecionaSUS, CONASS, SES-GO | ID: biblio-1116448

ABSTRACT

No Brasil, em diversos municípios de diferentes estados, no período da pandemia de Infecção por Coronavírus, até a publicação deste material, tem sido relatada a distribuição dos chamados "KIT-COVID", que se tratam de kits de medicamentos para serem usados como profilaxia ao contágio e/ou aos primeiros sintomas da infecção pelo novo Coronavírus (SARS-CoV-2). Os kits tem composição variável, sendo que os medicamentos incluídos com mais frequência são: cloroquina ou hidroxicloroquina, ivermectina, azitromicina, prednisona (ou outro corticosteroide). Além da variação de combinação de medicamentos que compõem o "KIT-COVID", também é variável a posologia e as orientações de uso. Alerta que, o uso de qualquer medicamento fora de sua indicação aprovada (off-label) deve ser uma decisão individual do médico, analisando caso a caso e compartilhando os possíveis benefícios e riscos com o paciente, e que é vedado ao médico a publicidade sobre tal conduta, de acordo com Código de Ética Médica, capítulo de Publicidade Médica: "Art. 113. Divulgar, fora do meio científico, processo de tratamento ou descoberta cujo valor ainda não esteja expressamente reconhecido cientificamente por órgão competente"


In Brazil, in several municipalities of different states, in the period of the Coronavirus Infection pandemic, until the publication of this material, the distribution of the so-called "KIT-COVID" has been reported, which are drug kits to be used as prophylaxis contagion and / or the first symptoms of infection with the new Coronavirus (SARS-CoV-2). The kits have a variable composition, and the drugs most frequently included are: chloroquine or hydroxychloroquine, ivermectin, azithromycin, prednisone (or another corticosteroid). In addition to the variation in the combination of drugs that make up the "KIT-COVID", the dosage and directions for use are also variable. Warns that the use of any medication outside its approved indication (off-label) must be an individual decision of the doctor, analyzing case by case and sharing the possible benefits and risks with the patient, and that the doctor is prohibited from advertising about such conduct, according to the Medical Ethics Code, Medical Advertising chapter: "Art. 113. Disclose, outside the scientific environment, a treatment or discovery process whose value is not yet expressly recognized scientifically by a competent body "


Subject(s)
Humans , Therapeutics , Behavior , Ivermectin , Brazil/epidemiology , Prednisone , Pharmaceutical Preparations , Chloroquine , Coronavirus Infections/epidemiology , Azithromycin , Drug Combinations , Pandemics , Hydroxychloroquine , Posology , Morbidity , Disease Transmission, Infectious , Advertising , Alert , Codes of Ethics , Products Distribution
18.
Brasília; s.n; 31 jul. 2020.
Non-conventional in Portuguese | LILACS, BRISA, PIE | ID: biblio-1117732

ABSTRACT

O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referentes ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 12 artigos e 6 protocolos.


Subject(s)
Humans , Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Betacoronavirus/drug effects , Technology Assessment, Biomedical , Immunoglobulins/therapeutic use , Vaccines/therapeutic use , Chloroquine/therapeutic use , Cross-Sectional Studies , Cohort Studies , Azithromycin/therapeutic use , Drug Combinations , Bevacizumab/therapeutic use , Hydroxychloroquine/therapeutic use
19.
Brasília; s.n; 30 jul. 2020.
Non-conventional in Portuguese | LILACS, BRISA, PIE | ID: biblio-1117730

ABSTRACT

O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referentes ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 14 artigos e 8 protocolos.


Subject(s)
Humans , Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Technology Assessment, Biomedical , Vitamin D/therapeutic use , Methylprednisolone/therapeutic use , Heparin/therapeutic use , Chloroquine/therapeutic use , Cross-Sectional Studies , Cohort Studies , Ritonavir/therapeutic use , Drug Combinations , Lopinavir/therapeutic use , Betacoronavirus/drug effects , Hydroxychloroquine/therapeutic use
20.
Brasília; s.n; 24 jul. 2020.
Non-conventional in Portuguese | LILACS, BRISA, PIE | ID: biblio-1117704

ABSTRACT

O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referentes ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 21 artigos e 15 protocolos.


Subject(s)
Humans , Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Betacoronavirus/drug effects , Technology Assessment, Biomedical , Immunoglobulins/therapeutic use , Methylprednisolone/therapeutic use , Vaccines/therapeutic use , Heparin/therapeutic use , Cohort Studies , Azithromycin/therapeutic use , Heparin, Low-Molecular-Weight/therapeutic use , Ritonavir/therapeutic use , Drug Combinations , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Mesenchymal Stem Cells , Darunavir/therapeutic use , Adalimumab/therapeutic use , Rituximab/therapeutic use , Infliximab/therapeutic use , Clopidogrel/therapeutic use , Ticagrelor/therapeutic use , Hydroxychloroquine/therapeutic use , Anticoagulants/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL